Remo Panaccione, MD, FRCPC

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.

Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.

Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.

Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.

Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.

Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.

Sara Horst, MD, MPH, comments on early introduction of biologics in the treatment of CD, highlighting her approach to initiating conversations with patients about advanced therapy.

Experts discuss the idea that, while symptoms of Crohn’s disease (CD) contribute to a patient’s quality of life, symptom control alone is not sufficient and the focus should be modifying the disease process.

Dr Sara Horst leads the discussion on the commonly followed treatment approach in the community for moderate to severe Crohn's Disease (CD) and highlights the factors that should guide treatment choices.

Jessica Allegretti, MD, MPH, and Edward Loftus Jr., MD, review emerging agents in the later phases for the management of IBD.

William Sandborn, MD, discusses various novel agents being investigated for the management of IBD.

Expert gastroenterologists review the unmet needs in IBD management.

Details of the head-to-head SEAVUE study of ustekinumab vs adalimumab for induction and maintenance therapy in patients with moderate to severe Crohn disease.

Edward Loftus Jr, MD, and William Sandborn, MD, review the 5-year remission data from the IM-UNITI trial for ustekinumab and post hoc analysis from the GEMINI 2 trial for vedolizumab in patients with Crohn disease.

A panel of experts share their experiences with the use of biologics for the treatment of inflammatory bowel diseases (IBDs).

Indications for surgery in treating patients for ulcerative colitis (UC) and Crohn disease.

Expert gastroenterologists share their perspectives regarding overall treatment approach in a patient with moderate- to high-risk inflammatory bowel disease.

Initial IBD therapy for a patient with low-risk disease and measuring treatment response on initial therapy.

Important patient factors to consider other than severity of disease when choosing a therapeutic agent for inflammatory bowel disease.

A panel of experts discuss the latest guidelines and how they make a treatment decision for patients with ulcerative colitis and Crohn’s disease.

Panel of gastroenterologists share their perspectives regarding the diagnostic work-up for patients who may have symptoms suggestive of IBD.

Expert opinions on the effect of the progressive, relapsing nature of inflammatory bowel disease on a patients’ quality of life.

Effect of age, gender, racial, and socioeconomic disparities on the incidence and prevalence of inflammatory bowel disease (IBD).

Expert gastroenterologists review the pathophysiology of inflammatory bowel disease (IBD) along with the associated risk factors.